Q3 2022 Results

Company overview Financial performance Financial review 2022 priorities Appendix Innovation: Clinical trials Innovation: Pipeline overview Novartis pipeline in Phase 1 Solid tumors Code Name 177Lu-NeoB Ac-PSMA-617 AAA603 AAA817 ADPT01 ADPT01 DFF332 DFF332 DKY709 DKY709 + spartalizumab DYP688 DYP688 IAG933 IAG933 JDQ443 JDQ443 KAZ954 KAZ954 MGY825 MGY825 NIS793 NIS793, spartalizumab NIZ985 NIZ985, spartalizumab NZV930 TNO155 TNO155 VPM087 WNT974 Mechanism Radioligand therapy target GRPR Radioligand therapy target PSMA HIF2A inhibitor Novel immunomodulatory agent GNAQ,GNA11 antagonist. KRAS inhibitor Indication(s) Hematology Name Code Multiple solid tumors ADPT03 Metastatic castration-resistant prostate cancer Colorectal cancer (combos) Renal cell carcinoma Cancers HDM201 ADPT03 HDM201 (combos) JBH492 JBH492 JEZ567 JEZ567 MAK683 MAK683 Unveal melanoma MBG453 sabatolimab Mesothelioma MIK665 MIK665 KRAS G12C mutated solid tumors VAY736 ianalumab + ibrutinib Solid tumors VOB560 VOB560 NSCLC WVT078 WVT078 YTB323 YTB323 NZV930, spartalizumab, NIR178 gevokizumab WNT974+ spartalizumab TGFB inhibitor IL-15 agonist CD73 antagonist SHP2 inhibitor Solid tumors Solid tumors Solid tumors Solid tumors (combo) IL-1 beta antagonist Porcupine inhibitor Solid tumors Colorectal cancer, 1st line Immunology Code Name FIA586 FIA586 MHS552 MHS552 MHV370 MHV370 NG1226 NG1226 Neuroscience Code NIO752 Mechanism Indication(s) Non-alcoholic steatohepatitis (NASH) Autoimmune indications Systemic lupus erythematosus Tendinopathy References Abbreviations 30 lead indications Lead indication Mechanism BCL11A MDM2 inhibitor CD123 CAR-T EED inhibitor TIM3 antagonist MCL1 inhibitor BAFF-R inhibitor CD19 CAR-T Indication(s) Sickle cell anemia Haematological malignancy Haematological malignancy Acute myeloid leukaemia Cancers Low risk myelodysplastic syndrome Hematological malignancies Haematological malignancy (combo) Cancers Multiple myeloma DLBCL and adult ALL Cardiovascular Code XXB750 Name XXB750 Mechanism Indication(s) Cardiovascular diseases Name Mechanism Others Code Global Health EDI048 EDI048 EYU688 EYU688 KAF156 INE963 ganaplacide INE963 Respiratory & Allergy NCJ424 NCJ424 Ophthalmology CpPI(4)K inhibitor NS4B inhibitor Indication(s) Cryptosporidiosis Dengue Malaria prophylaxis Malaria, uncomplicated Respiratory diseases Name NIO752 Mechanism Indication(s) Tau antagonist Progressive supranuclear palsy MHU650 37 Investor Relations | Q3 2022 Results MHU650 Diabetic eye diseases NOVARTIS | Reimagining Medicine

View entire presentation